Welcome to our dedicated page for BioNxt Solutions news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
BioNxt Solutions Inc. (BNXTF) is a bioscience innovator developing advanced drug delivery platforms for autoimmune and neurological conditions. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on BioNxt’s sublingual thin-film technologies, transdermal delivery systems, and regulatory progress across global markets. Key updates include partnership agreements with European CRDMOs, intellectual property filings, and clinical pipeline advancements targeting conditions like multiple sclerosis and lupus nephritis.
All content undergoes strict verification to ensure accuracy and relevance. Regular updates cover:
• Strategic collaborations with pharmaceutical partners
• Regulatory submissions and quality compliance achievements
• Product development milestones in drug delivery innovation
• Intellectual property portfolio expansions
Bookmark this page for direct access to BioNxt’s official communications and analyzed market developments. For comprehensive investment research, combine these updates with SEC filings and financial disclosures.
BioNxt Solutions Inc. (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) has provided an update on its flagship sublingual Cladribine drug formulation program for Multiple Sclerosis (MS) treatment. The company reported positive results from animal toxicity and pharmacokinetics studies, with plans for a human comparative bioequivalence study in early Q1 2025.
BioNxt also announced a positive international examination report from the European Patent Office for its patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases. The company expects EU patent grant within four weeks and plans to file in other major jurisdictions.
Additionally, BioNxt confirmed Myasthenia Gravis as its second clinical indication using anticancer compounds in a sublingual drug delivery system. The company has also engaged two consultants for investor relations activities starting October 1, 2024, for a six-month period.
BioNxt Solutions Inc. (CSE:BNXT, OTC PINK:BNXTF, FSE:BXT) has received a positive international examination report from the European Patent Office for its patent application on sublingual delivery of anticancer drugs for treating autoimmune neurodegenerative diseases. The company expects EU patent grant within eight weeks and plans to enter the national phase of the PCT process in multiple jurisdictions.
BioNxt's lead program focuses on developing a proprietary orally dispersible film (ODF) Cladribine dosage form for the multiple sclerosis (MS) market. The company is also expanding into Myasthenia Gravis (MG) treatment using anticancer compounds in ODF delivery systems. Both MS and MG patients often experience dysphagia, potentially giving ODF drug products an advantage over conventional tablets.
The global MS drug market is projected to reach $41 billion by 2033, while the MG market is expected to hit $6.7 billion by 2032. The broader market for CNS disease treatments is anticipated to grow to $238.8 billion by 2032.
BioNxt Solutions Inc. (CSE:BNXT, OTCQB:BNXTF, FSE:BXT) has signed a non-binding letter of intent (LOI) with Gen-Plus GmbH & Co KG, a German-based international contract research, development, and manufacturing company. The LOI outlines potential collaborations in areas such as intellectual property development, clinical trial planning, and thin film commercial manufacturing.
BioNxt is developing a proprietary oral dissolving film (ODF) Cladribine dosage form for the multiple sclerosis (MS) market. Cladribine tablets are currently approved in over 75 countries, with annual sales exceeding $1 billion USD. The global MS drug market is projected to reach $41 billion by 2033. BioNxt has filed provisional patent applications for its Cladribine ODF, with potential patent protection extending to 2044.
BioNxt Solutions Inc. (CSE:BNXT, OTCQB:BNXTF, FSE:BXT) has signed a statement of work (SOW) with a German-based international contract research, development, and manufacturing organization (CRDMO) for its Cladribine oral dissolvable film (ODF) development program. The SOW includes key deliverables such as technology transfer, GMP material production, stability testing, and preparation for EU submission.
BioNxt is developing a proprietary ODF Cladribine dosage form for the multiple sclerosis (MS) market, which has an expected global value of USD 41 billion by 2033. Cladribine tablets are currently approved in over 75 countries, including by the FDA and EMA, with annual sales exceeding USD 1 billion. The company has filed provisional patent applications for its Cladribine ODF, with potential protection extending to 2044.
BioNxt Solutions has signed a master services agreement (MSA) with a German international contract research, development, and manufacturing organization (CRDMO) to advance its pipeline of oral dissolvable (ODF) drug formulations.
The CRDMO, based in Munich, Germany, offers certified services and manufacturing capabilities across five countries. BioNxt aims to leverage this agreement to progress its proprietary ODF Cladribine dosage form for the multiple sclerosis (MS) market.
Cladribine tablets, already approved in over 75 countries, including by the FDA and EMA, have annual sales exceeding $1 billion. BioNxt plans to file additional patent applications for Cladribine ODF by early 2025, potentially extending patent protection to 2044.
This agreement facilitates BioNxt's regulatory, technical, and laboratory needs, setting the stage for a human comparative bioequivalence study.
BioNxt Solutions announced the closure of the second tranche of its non-brokered private placement, issuing 1,000,000 common shares at $0.27 each, raising $270,000.
The overall offering aims to issue a maximum of 6,000,000 shares to gather up to $1,620,000. Net proceeds will fund research, development, commercialization, and general working capital.
The company paid $21,600 in cash finder's fees and issued 80,000 non-transferable Common Share purchase warrants, exercisable at $0.36 per share for 24 months.
Securities issued are subject to a statutory hold period of four months plus a day.
FAQ
What is the current stock price of BioNxt Solutions (BNXTF)?
What is the market cap of BioNxt Solutions (BNXTF)?
